EUCTR2014-005595-28-DE进行中（未招募）1 期
Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial. - NeoIntercal
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with histologically or cytologically confirmed non-squamous non-small-cell lung cancer (NSCLC) stage II, IIIA and IIIB detected preoperatively by adequate methods and activating EGFR mutation in exons 18-21. Stage should be confirmed by PET-CT as well as adequate mediastinal staging. Routine MRI of the brain to exclude CNS-metastases is mandatory before enrolment according to standard guidelines.
- •2. At least one unidimensionally measurable lesion meeting RECIST criteria (version 1.1)
- •3. Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- •4. Estimated life expectancy of at least 12 weeks
- •5. Patients aged = 18 years
- •6. Adequate organ function including the following:
- •a) Adequate bone marrow reserve:
- •– absolute neutrophils (segmented and bands) count (ANC) =1.5x10e9/L;
- •– platelets =100x10e9/L;
- •– haemoglobin =9 g/dL.
- •b) Hepatic:
- •– bilirubin = 1xULN;
- •– alkaline phosphatase (AP) = 2.5xULN;
- •– aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5xULN.
- •– serum creatinine = 1.3 mg/dL;
- •– glomerular filtration rate = 70 mL/min (calculated) for cisplatinum based CTx. If contraindications including GFR below 70mL/min against cisplatin exist, carboplatin may also be used.
- •- glomerular filtration rate = 30 mL/min (calculated) if carboplatin is to be used
- •7. Cooperation and willingness to complete all aspects of the study
- •8. Written informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. EGFR wild type configuration
- •2. EGFR resistance mutations (i.e. T790M)
- •3. Significant cardiovascular disease, such as uncontrolled hypertension, myocardial infarction within the last 6 months, unstable angina pectoris, CHF = NYHA 2, serious arrhythmia, significant peripheral vascular disease
- •3. Pre-existing neuropathia = grade 2 (NCI CTCAE V4.03)
- •5. Patients with confirmed HIV infection
- •6. Prior history of malignancy except for basal cell carcinoma or carcinoma in situ of the cervix, and with the exception of other malignancies after curative treatment with an interval of at least 3 years.
- •7. Lactating or pregnant women, women of child-bearing potential who do not agree to the usage of highly effective contraception methods (allowed methods of contraception, meaning methods with a rate of failure of less than 1% per year are implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner). Women of childbearing potential must have a negative pregnancy test (serum ß-hCG) at Pre-Screening and Screening.
- •8. Any other chemotherapy at start
- •9. Treatment with other experimental drugs during the course of the study or within the last 30 days or 7 half-lifes of previously used trial medication, whatever is of longer duration, prior study start
- •10. Any psychiatric illness that would affect the patient’s ability to understand the demands of the clinical trial
- •11. Parallel participation in another clinical trial or participation in another clinical trial within the last 30 days or 7 half-lifes, whatever is of longer duration, prior study start
- •12. Patient has already been recruited in this trial
- •13. Patients who do not understand the nature, the scope and the consequences of the clinical trial
- •14. Affected persons who might be dependent on the sponsor or the investigator
- •14. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
研究者
相似试验
终止
2 期
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIBNon-squamous Non-small Cell Lung Cancer Stage IINon-squamous Non-small Cell Lung Cancer Stage IIIANon-squamous Non-small Cell Lung Cancer Stage IIIBActivating EGFR MutationNSCLCNCT02326285AIO-Studien-gGmbH1
已完成
2 期
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutationon-small cell lung cancerJPRN-UMIN000005086ung Oncology Group in Kyushu, Japan (LOGIK)21
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
已完成
2 期
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutationsnon-small cell lung cancerJPRN-C000000184Hokkaido Lung Cancer Clinical Study Group16